Tejas Patil, MD
Assistant Professor, Medicine-Medical Oncology

Photo
Medical School:
  • MD, Keck School of Medicine of the University of Southern California (2013)
Undergraduate School:
  • BA, University of Pennsylvania (Philadelphia, PA) (2007)
Internship:
  • University of Colorado (2013)
Residency:
  • University of Colorado, Internal Medicine (2016)
Fellowships:
  • University of Colorado, Hematology and Oncology (2020)
Department: Medicine-Medical Oncology

Professional Titles

  • Assistant Professor

Recognition & Awards

  • IASLC John Fisher Young Investigator Award, International Association for Lung Cancer (IASLC) (2019)
    The objective of the IASLC Foundation John’s Legacy Fellowship Award is to fund highly innovative proposals for the early detection and screening of lung cancer.

Teaching

  • Assistant Professor (2020)
    School of Medicine, Medicine

Publications

  • Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, Sinha S, Pollom EL, Nagpal S, Camidge DR, Rusthoven CG, Braunstein SE, Wakelee HA, McCoach CE. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J Thorac Oncol. 2022 Jan;17(1):116-129. PubMed PMID: 34455066
  • Tsui DCC, Kavanagh BD, Honce JM, Rossi C, Patil T, Camidge DR. Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib. Clin Lung Cancer. 2022 Jan;23(1):e5-e8. PubMed PMID: 34246540
  • Patil T, Nie Y, Aisner DL, Camidge DR. Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology. Front Oncol. 2021;11:788245. PubMed PMID: 35070994
  • Peters TL, Patil T, Le AT, Davies KD, Brzeskiewicz PM, Nijmeh H, Bao L, Camidge DR, Aisner DL, Doebele RC. Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. NPJ Precis Oncol. 2021 Oct 12;5(1):91. PubMed PMID: 34642436
  • Choudhury NJ, Schneider JL, Patil T, Zhu VW, Goldman DA, Yang SR, Falcon CJ, Do A, Nie Y, Plodkowski AJ, Chaft JE, Digumarthy SR, Rekhtman N, Arcila ME, Iasonos A, Ou SI, Lin JJ, Drilon A. Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1 -Rearranged Lung Cancers. JTO Clin Res Rep. 2021 Jul;2(7):100187. PubMed PMID: 34590036
  • Gurule NJ, McCoach CE, Hinz TK, Merrick DT, Van Bokhoven A, Kim J, Patil T, Calhoun J, Nemenoff RA, Tan AC, Doebele RC, Heasley LE. A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. NPJ Precis Oncol. 2021 May 17;5(1):41. PubMed PMID: 34001994
  • Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Jänne PA, Aguirre AJ. Acquired Resistance to KRAS(G12C) Inhibition in Cancer. N Engl J Med. 2021 Jun 24;384(25):2382-2393. PubMed PMID: 34161704
  • Schenk EL, Patil T, Pacheco J, Bunn PA Jr. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist. 2021 Mar;26(3):e454-e472. PubMed PMID: 33179378
  • Patil T, Pacheco JM, Dimou A, Purcell WT, Rossi C, Bunn PA, Doebele RC, Camidge DR, Ferrigno L. Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR -Mutant Non-small Cell Lung Cancer. Front Oncol. 2020;10:510. PubMed PMID: 32351892
  • Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May;21(3):e191-e204. PubMed PMID: 31859066
  • Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May;21(3):e191-e204. PubMed PMID: 31859066
  • Reckamp KL, Patil T, Kirtane K, Rich TA, Espenschied CR, Weipert CM, Raymond VM, Santana-Davila R, Doebele RC, Baik CS. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clin Lung Cancer. 2020 Nov;21(6):545-552.e1. PubMed PMID: 32665165
  • Schenk EL, Patil T, Pacheco J, Bunn PA Jr. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist. 2020 Nov 11. [Epub ahead of print] PubMed PMID: 33179378
  • Hararah MK, Stokes WA, Oweida A, Patil T, Amini A, Goddard J, Bowles DW, Karam SD. Epidemiology and treatment trends for primary tracheal squamous cell carcinoma. Laryngoscope. 2020 Feb;130(2):405-412. PubMed PMID: 30977524
  • Johanna C. Bendell, Kian-Huat Lim, Mark E. Burkard, Jessica J. Lin, Young Kwang Chae, Mark A. Socinski, Gazala Khan, Karen L. Reckamp, Shawn Leland, Douglas Plessinger, Lori Kunkel, Efrat Dotan, Gregory Otterson, Sai-Hong Ignatius Ou, Tejas Patil, John V. Heymach, Edward S. Kim. CRESTONE – Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions – A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210) [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2020 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2020;80(22 Suppl):Abstract nr PO-003
  • Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, Camidge DR. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Cancer. 2019 Apr 1;125(7):1038-1049. PubMed PMID: 30548240
  • Ng TL, Smith DE, Mushtaq R, Patil T, Dimou A, Yang S, Liu Q, Li X, Zhou C, Jones RT, Tu MM, Yan F, Bowman IA, Liu SV, Newkirk S, Bauml J, Doebele RC, Aisner DL, Gao D, Ren S, Camidge DR. ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. J Thorac Oncol. 2019 Apr;14(4):596-605. PubMed PMID: 30543838
  • Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW. Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs Today (Barc). 2019 Oct;55(10):641-652. PubMed PMID: 31720561
  • Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol. 2018 Nov;13(11):1717-1726. PubMed PMID: 29981925
  • Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, Camidge DR. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018 Jan;13(1):134-138. PubMed PMID: 28843358
  • Ziemke M, Patil T, Nolan K, Tippimanchai D, Malkoski SP. Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer. 2017 Jul;109:28-35. PubMed PMID: 28577946
  • Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer. 2016 Jun;96:27-32. PubMed PMID: 27133746
View All (22 Total) View Less

Professional Memberships

  • American College of Physicians (ACP), Member
  • American Medical Association (AMA), Member
  • American Society of Clinical Oncology (ASCO), Member
  • American Association of Cancer Research (AACR), Member
  • International Association for the Study of Lung Cancer (IASLC), Member
  • National Comprehensive Cancer Network (NCCN), Member
  • European Society for Clinical Oncology (ESMO), Member
  • Rocky Mountain Cancer Society, President Elect

Practice Locations

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

UCHealth Lung Cancer Clinic - Anschutz Medical Campus
1665 Aurora Ct
Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (2016)
  • Hematology and Oncology, Board Certification (2020)
Conditions & Treatments
  • Cancers - Lung Cancer
  • Cancers
  • Cancers - Cancer Medicine
Clinical Interests
My clinical and research interests include a focus on precision oncology in the management of patients with lung cancers. I am particularly interested in novel biomarker development, management of patients with oncogene driven cancer (such as ALK, ROS1, EGFR, MET, etc.), development of targeted therapies, and understanding mechanisms of acquired resistance.

Care Philosophy
I believe that there is no "one-size fits all" approach in medicine, especially with cancer therapy. I strive to use the best scientific principles available and tailor these to the individual needs and circumstances of each patient.

Personal Interests
I am interested in targeted therapies and novel biomarkers. My true passion outside of medicine is classical piano performance. I also dabble with sketch comedy, film, and skiing on the side.

Public Speaking
Yes
I have given multiple lectures on advances in precision oncology, targeted therapies and acquired resistance.

General Information

Medical Schools:
  • MD, Keck School of Medicine of the University of Southern California (2013)
Undergraduate Schools:
  • BA, University of Pennsylvania (Philadelphia, PA) (2007)
Internships:
  • University of Colorado (2013)
Residency Programs:
  • University of Colorado, Internal Medicine (2016)
Fellowships:
  • University of Colorado, Hematology and Oncology (2020)
Department: Medicine-Medical Oncology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;